Monika A Davare

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8044120/publications.pdf

Version: 2024-02-01

55 papers	4,864 citations	147726 31 h-index	155592 55 g-index
56 all docs	56 docs citations	56 times ranked	6723 citing authors

#	Article	IF	Citations
1	An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9093-9098.	3.3	495
2	A beta 2 Adrenergic Receptor Signaling Complex Assembled with the Ca2+ Channel Cav1.2. Science, 2001, 293, 98-101.	6.0	489
3	SAP97 Is Associated with the Î±-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor GluR1 Subunit. Journal of Biological Chemistry, 1998, 273, 19518-19524.	1.6	385
4	An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling. Molecular and Cellular Neurosciences, 2010, 43, 146-156.	1.0	242
5	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2020, 26, 2654-2663.	3.2	230
6	Activity-Dependent Synaptogenesis: Regulation by a CaM-Kinase Kinase/CaM-Kinase I/Î²PIX Signaling Complex. Neuron, 2008, 57, 94-107.	3.8	200
7	Mitogen- and Stress-Activated Protein Kinase 1 Mediates cAMP Response Element-Binding Protein Phosphorylation and Activation by Neurotrophins. Journal of Neuroscience, 2004, 24, 4324-4332.	1.7	188
8	Regulation of Axonal Extension and Growth Cone Motility by Calmodulin-Dependent Protein Kinase I. Journal of Neuroscience, 2004, 24, 3786-3794.	1.7	177
9	Protein Phosphatase 2A Is Associated with Class C L-type Calcium Channels (Cav1.2) and Antagonizes Channel Phosphorylation by cAMP-dependent Protein Kinase. Journal of Biological Chemistry, 2000, 275, 39710-39717.	1.6	164
10	Long-Term Potentiation-Dependent Spine Enlargement Requires Synaptic Ca²⁺-Permeable AMPA Receptors Recruited by CaM-Kinase I. Journal of Neuroscience, 2010, 30, 11565-11575.	1.7	164
11	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clinical Cancer Research, 2016, 22, 2351-2358.	3.2	141
12	ROS1-dependent cancers â€" biology, diagnostics and therapeutics. Nature Reviews Clinical Oncology, 2021, 18, 35-55.	12.5	134
13	The A-kinase Anchor Protein MAP2B and cAMP-dependent Protein Kinase Are Associated with Class C L-type Calcium Channels in Neurons. Journal of Biological Chemistry, 1999, 274, 30280-30287.	1.6	133
14	Critical Role of cAMP-Dependent Protein Kinase Anchoring to the L-Type Calcium Channel Cav1.2 via A-Kinase Anchor Protein 150 in Neuronsâ€. Biochemistry, 2007, 46, 1635-1646.	1.2	126
15	Follicle-stimulating Hormone Activates Extracellular Signal-regulated Kinase but Not Extracellular Signal-regulated Kinase Kinase through a 100-kDa Phosphotyrosine Phosphatase. Journal of Biological Chemistry, 2003, 278, 7167-7179.	1.6	122
16	Increased phosphorylation of the neuronal L-type Ca2+ channel Cav1.2 during aging. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 16018-16023.	3.3	117
17	Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19519-19524.	3.3	106
18	Analysis of CaM-kinase signaling in cells. Cell Calcium, 2011, 50, 1-8.	1.1	99

#	Article	IF	Citations
19	Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5381-90.	3.3	93
20	SAP97 concentrates at the postsynaptic density in cerebral cortex. European Journal of Neuroscience, 2000, 12, 3605-3614.	1.2	92
21	Bidirectional Regulation of Cytoplasmic Polyadenylation Element-Binding Protein Phosphorylation by Ca2+/Calmodulin-Dependent Protein Kinase II and Protein Phosphatase 1 during Hippocampal Long-Term Potentiation. Journal of Neuroscience, 2005, 25, 5604-5610.	1.7	82
22	Transient Receptor Potential Canonical 5 Channels Activate Ca²⁺/Calmodulin Kinase Iî³ to Promote Axon Formation in Hippocampal Neurons. Journal of Neuroscience, 2009, 29, 9794-9808.	1.7	81
23	Mouse model of intrahepatic cholangiocarcinoma validates FIGâ€“ROS as a potent fusion oncogene and therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19513-19518.	3.3	66
24	Leptin-Induced Spine Formation Requires TrpC Channels and the CaM Kinase Cascade in the Hippocampus. Journal of Neuroscience, 2014, 34, 10022-10033.	1.7	61
25	A Genome-Wide Screen of CREB Occupancy Identifies the RhoA Inhibitors Par6C and Rnd3 as Regulators of BDNF-Induced Synaptogenesis. PLoS ONE, 2013, 8, e64658.	1.1	57
26	Inhibition of Calcium/Calmodulin-dependent Protein Kinase Kinase by Protein 14-3-3. Journal of Biological Chemistry, 2004, 279, 52191-52199.	1.6	52
27	Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. Oncotarget, 2015, 6, 18921-18932.	0.8	45
28	Statins decrease dendritic arborization in rat sympathetic neurons by blocking RhoA activation. Journal of Neurochemistry, 2009, 108, 1057-1071.	2.1	44
29	Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia, 2018, 32, 2374-2387.	3.3	43
30	Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clinical Cancer Research, 2018, 24, 6471-6482.	3.2	42
31	ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells. Molecular and Cellular Biochemistry, 2010, 335, 155-171.	1.4	35
32	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. Clinical Cancer Research, 2020, 26, 2932-2945.	3.2	35
33	NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Communications Biology, 2020, 3, 776.	2.0	34
34	Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma. Journal of Neuro-Oncology, 2011, 105, 475-483.	1.4	31
35	Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma. Molecular Cancer Research, 2019, 17, 676-685.	1.5	30
36	Detecting and targetting oncogenic fusion proteins in the genomic era. Biology of the Cell, 2015, 107, 111-129.	0.7	29

#	Article	IF	Citations
37	Revisiting NTRKs as an emerging oncogene in hematological malignancies. Leukemia, 2019, 33, 2563-2574.	3.3	28
38	Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. Blood, 2020, 135, 2159-2170.	0.6	22
39	IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma. Scientific Reports, 2016, 6, 27012.	1.6	21
40	Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research, 2015, 75, 2146-2150.	0.4	20
41	Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics, 2022, 21, 336-346.	1.9	20
42	Calmodulin-kinases regulate basal and estrogen stimulated medulloblastoma migration via Rac1. Journal of Neuro-Oncology, 2011, 104, 65-82.	1.4	19
43	Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. Oncogene, 2015, 34, 2991-2999.	2.6	10
44	RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	9
45	Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion. Journal of Physical Education and Sports Management, 2021, 7, a006109.	0.5	9
46	A targeted combinatorial therapy for Ewing's sarcoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 37, 102446.	1.7	6
47	Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Journal of Physical Education and Sports Management, 2022, 8, a006140.	0.5	6
48	MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. Molecular Cancer Research, 2022, 20, 722-734.	1.5	6
49	Preclinical Testing of Tandutinib in a Transgenic Medulloblastoma Mouse Model. Journal of Pediatric Hematology/Oncology, 2012, 34, 116-121.	0.3	5
50	Discovery and Validation of a Compound to Target Ewingâ€™s Sarcoma. Pharmaceutics, 2021, 13, 1553.	2.0	5
51	Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells. Biochemical and Biophysical Research Communications, 2014, 450, 555-560.	1.0	4
52	A ribose modification of Spinach aptamer accelerates lead(ii) cation association in vitro. Chemical Communications, 2019, 55, 5882-5885.	2.2	4
53	Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYCâ€amplified model cell line. Pediatric Blood and Cancer, 2017, 64, e26553.	0.8	2
54	A Broccoli aptamer chimera yields a fluorescent K+ sensor spanning physiological concentrations. Chemical Communications, 2021, 57, 1344-1347.	2.2	2

#	Article	IF	Citations
55	A blast from the past:ROS1on the brain. Oncotarget, 2019, 10, 1664-1666.	0.8	2